A Study of Imlunestrant (LY3484356) in Female Healthy Participants
Status:
Not yet recruiting
Trial end date:
2022-10-30
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the effect of imlunestrant on repaglinide,
omeprazole and dextromethorphan, and rosuvastatin and digoxin. The study will also
investigate the effect of quinidine on imlunestrant in female healthy participants of
non-childbearing potential. The safety and tolerability of imlunestrant will be investigated
in female healthy participants of non-childbearing potential. The study will last
approximately up to 32 days for each participant excluding the screening period.